CYRXNasdaqPharmaceutical PreparationsFiscal year ends December 31

Cryoport, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026

$16.98+0.14 (+0.83%)

Close on Oct 19, 2026

Market cap: $856.52M
P/E (TTM): –
Dividend yield: –

Cryoport, Inc. income statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31	FY 2018 2018-12-31	FY 2016 2016-03-31	FY 2015 2015-03-31	FY 2014 2014-03-31	FY 2013 2013-03-31	FY 2012 2012-03-31	FY 2011 2011-03-31
Revenue	176	157	169	237	223	79	34	20	5.88	3.94	2.66	1.10	0.56	0.48
Cost of Revenue	93	87	93	133	126	42	17	9.39	3.99	2.77	2.22	1.59	1.39	1.30
Gross Profit	83	70	75	104	97	36	17	10	1.89	1.17	0.44	-0.49	-0.84	-0.83
Research & Development	17	18	18	16	17	9.48	3.74	1.84	0.55	0.35	0.41	0.43	0.49	0.45
Selling, General & Admin	103	110	108	120	98	57	31	17	10	6.41	5.11	5.41	6.11	4.32
Selling & Marketing	–	–	–	–	–	–	14	7.25	4.16	2.91	–	–	–	–
General & Administrative	–	–	–	–	–	–	17	9.80	5.93	3.50	–	–	–	–
Operating Expenses	120	191	176	136	114	66	35	19	11	6.76	5.52	5.84	6.60	4.77
Operating Income	-37	-122	-101	-32	-18	-30	-18	-8.64	-8.74	-5.59	-5.08	-6.32	-7.43	-5.60
Interest Expense	2.36	3.98	5.58	6.14	4.69	2.56	1.37	0.07	1.07	1.43	0.78	0.07	0.53	0.62
Interest & Investment Income	–	–	–	–	–	–	–	–	–	–	–	0	0.01	0.02
Other Non-Operating Income	4.64	17	16	-3.19	-256	-2.73	-0.60	-0.89	-0.01	0.00	-0.01	-0.06	-0.40	-0.55
Asset Impairment Charges	0	64	50	–	0	–	–	–	–	–	–	–	–	–
Gain (Loss) on Sale of Assets	117	-0.38	-0.95	-0.80	-0.54	-0.38	-0.27	-0.40	-0.17	-0.02	-0.02	-0.05	-0.01	–
Pretax Income	-32	-104	-84	-35	-274	-33	-18	-9.54	-9.82	-7.03	-20	-6.38	-7.83	-6.15
Income Tax Expense	1.80	0.36	0.35	2.24	1.69	-0.05	0.06	0.02	0.00	0.00	0.00	0.00	0.00	0.00
Income from Continuing Operations	-34	-105	-85	–	–	–	–	–	–	–	–	–	–	–
Income from Discontinued Operations	112	-10	-15	–	–	–	–	–	–	–	–	–	–	–
Net Income incl. Noncontrolling Interests	78	-115	-100	-37	-276	-33	-18	-9.56	–	–	–	–	–	–
Net Income	78	-115	-100	-37	-276	-33	-18	-9.56	-9.82	-7.03	-20	-6.38	-7.83	-6.15
Preferred Dividends	–	–	–	–	–	–	–	–	0.76	0.31	0	–	–	–
Net Income to Common	70	-123	-108	-45	-284	-75	-18	–	-15	-12	-20	-6.38	–	–
EPS (Basic)(per share)	1.40	-2.49	-2.21	-0.93	-6.18	-1.94	-0.55	-0.34	-2.05	-2.44	-4.81	-2.04	-3.24	-5.52
EPS (Diluted)(per share)	1.40	-2.49	-2.21	-0.93	-6.18	-1.94	-0.55	-0.34	-2.05	-2.44	-4.81	-2.04	-3.24	-5.52
Shares Outstanding (Basic, Weighted)(shares)	50	49	49	49	46	39	33	28	7.34	5.01	4.07	3.15	2.41	1.11
Shares Outstanding (Diluted, Weighted)(shares)	50	49	49	49	46	39	33	28	7.34	5.01	4.07	3.15	2.84	1.11
EBITDA	-9.09	-91	-73	-9.14	2.42	-20	-15	-7.79	-8.50	-5.40	-4.77	-5.93	-7.09	-5.35
Provision for Credit Losses	–	–	0.82	0.23	0.03	–	–	–	–	–	–	–	–	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: 47.1%
Operating margin: -21.2%
Net margin: -20.1%
Return on equity, FY2025: 17.3%

Financial strength

Current ratio: 2.08
Debt to equity: 0.00
Debt to assets: 0.1%
Cash to current liabilities: 121.8%

Valuation

P/E ratio: –
Price to sales: 4.59
Price to book: 1.75
Dividend yield: –